FibroGen Company Profile (NASDAQ:FGEN)

Analyst Ratings

Consensus Ratings for FibroGen (NASDAQ:FGEN) (?)
Ratings Breakdown: 1 Hold Rating(s), 3 Buy Rating(s)
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $33.50 (75.12% upside)

Analysts' Ratings History for FibroGen (NASDAQ:FGEN)
Show:
DateFirmActionRatingPrice TargetActions
7/12/2016Credit Suisse Group AGReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/22/2016Goldman Sachs Group Inc.Lower Price Target$34.00 -> $31.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/29/2015Leerink SwannReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/4/2015Citigroup Inc.Initiated CoverageBuy$40.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/23/2015Lake Street CapitalInitiated CoverageHold$25.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/9/2014Stifel NicolausInitiated CoverageBuy$39.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/9/2014Royal Bank Of CanadaInitiated CoverageOutperform$38.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/8/2014William BlairInitiated CoverageOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/29/2014 forward)

Earnings

Earnings History for FibroGen (NASDAQ:FGEN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/11/2016        
5/9/2016Q116($0.56)($0.45)$17.74 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/29/2016Q4($0.54)($0.85)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2015Q3($0.61)($0.74)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2015Q215$0.73$0.83$111.75 million$120.55 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2015Q115($0.52)($0.78)$34.00 million$16.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/26/2015Q414($0.90)($0.82)$16.49 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for FibroGen (NASDAQ:FGEN)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164($0.84)($0.59)($0.70)
Q2 20164$0.15$0.43$0.30
Q3 20163($0.61)($0.41)($0.51)
Q4 20163($0.73)($0.60)($0.67)
Q1 20171($0.72)($0.72)($0.72)
Q2 20171($0.73)($0.73)($0.73)
Q3 20171($0.74)($0.74)($0.74)
Q4 20171($0.80)($0.80)($0.80)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for FibroGen (NASDAQ:FGEN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for FibroGen (NASDAQ:FGEN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
7/27/2016Thomas B NeffCEOSell37,798$18.38$694,727.24View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/13/2016Thomas B NeffCEOSell27,000$17.50$472,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/29/2016Thomas B NeffCEOSell27,000$16.02$432,540.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2016Pat CotroneoCFOSell1,796$16.49$29,616.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2016Thomas B NeffCEOSell27,000$16.48$444,960.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/10/2016K Peony YuInsiderSell2,344$17.96$42,098.24View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/3/2016Thomas B NeffCEOSell27,000$18.99$512,730.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/20/2016Thomas B NeffCEOSell27,000$17.68$477,360.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/16/2016Pat CotroneoCFOSell6,107$17.60$107,483.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/3/2016Thomas B NeffCEOSell27,000$17.78$480,060.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/20/2016Thomas B NeffCEOSell27,000$19.98$539,460.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/19/2016Thomas B NeffCEOSell13,500$20.21$272,835.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/5/2016Thomas B NeffCEOSell27,000$21.11$569,970.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2016Frank H Md ValoneInsiderSell10,750$21.11$226,932.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/22/2016Thomas B NeffCEOSell27,000$18.74$505,980.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/8/2016Thomas B NeffCEOSell27,000$19.62$529,740.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/1/2016Frank H Md ValoneInsiderSell10,750$16.84$181,030.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/23/2016Thomas B NeffCEOSell27,000$19.11$515,970.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/22/2016Thomas B NeffCEOSell13,500$19.81$267,435.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/16/2016Frank H. Md ValoneinsiderSell10,750$18.41$197,907.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/10/2016Thomas B. NeffCEOSell27,000$15.31$413,370.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/29/2016Thomas B. NeffCEOSell27,000$19.41$524,070.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/21/2016Thomas F Kearns JrDirectorSell1,572$22.08$34,709.76View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/14/2016Thomas B. NeffCEOSell27,000$23.69$639,630.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/24/2015Thomas F. Kearns, Jr.DirectorSell7,800$30.88$240,864.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/23/2015Thomas B. NeffCEOSell27,000$30.10$812,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/11/2015Thomas B. NeffCEOSell27,000$29.59$798,930.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/10/2015K Peony YuVPSell1,093$28.96$31,653.28View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/8/2015Miguel MaderoDirectorSell40,386$30.49$1,231,369.14View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/30/2015K Peony YuVPSell5,000$30.00$150,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/25/2015Pat CotroneoCFOSell5,000$30.00$150,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/24/2015Thomas B. NeffCEOSell13,500$28.98$391,230.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/24/2015Thomas F. Kearns, Jr.DirectorSell3,900$29.00$113,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/23/2015Thomas B. NeffCEOSell13,500$27.99$377,865.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/23/2015Thomas F. Kearns, Jr.DirectorSell3,900$28.02$109,278.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/17/2015K Peony YuVPSell5,000$28.00$140,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/10/2015K Peony YuVPSell5,000$25.62$128,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/9/2015K Peony YuVPSell2,500$25.00$62,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/2/2015Frank H. Md ValoneinsiderSell10,000$23.18$231,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/30/2015Thomas B. NeffCEOSell27,000$24.06$649,620.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/21/2015Thomas F. Kearns, Jr.DirectorSell7,800$23.83$185,874.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/19/2015Frank H. Md ValoneinsiderSell10,000$23.00$230,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/19/2015K Peony YuVPSell5,000$24.00$120,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/16/2015K Peony YuVPSell5,000$21.46$107,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/16/2015Thomas B. NeffCEOSell27,000$21.86$590,220.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/2/2015Thomas B. NeffCEOSell27,000$21.59$582,930.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2015Frank H. Md ValoneinsiderSell10,000$21.38$213,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/18/2015Thomas B. NeffCEOSell27,000$29.10$785,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/15/2015Pat CotroneoCFOSell1,093$27.95$30,549.35View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/14/2015Rory B. RiggsDirectorSell50,000$27.61$1,380,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/11/2015Miguel MaderoDirectorSell20,600$27.66$569,796.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/10/2015K Peony YuVPSell1,093$27.84$30,429.12View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/10/2015Pat CotroneoCFOSell7,500$27.33$204,975.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/4/2015Thomas B. NeffCEOSell13,500$22.88$308,880.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/3/2015Thomas B. NeffCEOSell13,500$22.92$309,420.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/1/2015Frank H. Md ValoneinsiderSell10,000$23.58$235,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/23/2015Thomas B NeffCEOSell27,000$24.71$667,170.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/20/2015Frank H Md ValoneInsiderSell1,000$23.70$23,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/20/2015Pat CotroneoCFOSell7,881$23.47$184,967.07View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/9/2015Thomas B NeffCEOSell27,000$22.11$596,970.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/6/2015K Peony YuVPSell5,381$22.69$122,094.89View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/25/2015Thomas B NeffCEOSell27,000$23.57$636,390.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for FibroGen (NASDAQ:FGEN)
DateHeadline
07/29/16 04:08 PMExpected For FibroGen, Inc (NASDAQ:FGEN) Sales Of $1071.09 - Investor Newswire
07/28/16 08:32 PMFibroGen, Inc (NASDAQ:FGEN) Trading Up – Insiders Selling, Short Interest Growing
07/26/16 04:59 AMAstellas and FibroGen Announce First Patient Treated in Phase 3 Studies and Positive Phase 2 Results of Roxadustat in ...
07/26/16 12:51 AM1:51 am FibroGen and Astellas (ALPMY) treats first patient in its Phase 3 trials of roxadustat in Japan -
07/25/16 09:34 PMAstellas and FibroGen Announce First Patient...
07/25/16 09:34 PMAstellas and FibroGen Announce First Patient Treated in Phase 3 Studies and Positive Phase 2 Results …
07/25/16 08:28 PMAstellas and FibroGen Announce First Patient Treated in Phase 3 Studies and Positive Phase 2 Results of Roxadustat in Patients with Chronic Kidney Disease in Japan - [at noodls] - TOKYO and SAN FRANCISCO, July 25, 2016 (GLOBE NEWSWIRE) -- Astellas Pharma Inc. (TSE:4503) ('Astellas') and FibroGen, Inc. (Nasdaq:FGEN) ('FibroGen'), today announced the dosing of the first patient in ...
07/21/16 09:33 PMIt Seems FibroGen Inc Will Go Up. Have Big Gap Up Today - Consumer Eagle
07/21/16 09:33 PMFibroGen, Inc (NASDAQ:FGEN): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/21/16 07:32 AMCould FibroGen Inc Lose Strenght? The Stock Increases A Lot Today - Consumer Eagle
07/21/16 07:08 AMFibroGen, Inc. breached its 50 day moving average in a Bullish Manner : FGEN-US : July 21, 2016 -
07/19/16 04:06 PMFibroGen Inc Realized Volatility Hits an Inflection Level - CML News
07/19/16 10:07 AMHow Many FibroGen Inc (NASDAQ:FGEN)'s Analysts Are Bullish? - Press Telegraph
07/19/16 10:07 AMShare Performance Summary for: FibroGen, Inc. (NASDAQ:FGEN) - Press Telegraph
07/19/16 10:07 AMEarnings Focus and Crowd Sourced Sentiment Review for FibroGen, Inc (NASDAQ:FGEN) - TGP
07/18/16 02:45 PMFibroGen, Inc. – Value Analysis (NASDAQ:FGEN) : July 18, 2016 -
07/16/16 07:25 AMShares Experiencing a Downtrend: FibroGen, Inc. (NASDAQ:FGEN) - TGP
07/15/16 05:17 AMFibroGen, Inc (NASDAQ:FGEN) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/14/16 07:19 AMAnalyst Target and Average Rating Watch: FibroGen, Inc (NASDAQ:FGEN) - Press Telegraph
07/12/16 09:21 PMFibroGen, Inc (NASDAQ:FGEN) Wall Street Analyst Recommendation Outlook - Telanagana Press
07/12/16 09:21 PMBulls and Bear in Spotlight- FibroGen (NASDAQ:FGEN), Juno Therapeutics (NASDAQ:JUNO), Kite Pharma (NASDAQ ... - Seneca Globe
07/11/16 08:48 AMStock Performance Rundown on: FibroGen, Inc. (NASDAQ:FGEN) - Press Telegraph
07/11/16 07:07 AMFibroGen, Inc. breached its 50 day moving average in a Bullish Manner : FGEN-US : July 11, 2016 -
07/07/16 09:13 PMFibroGen, Inc (NASDAQ:FGEN) Expected To Post Sales Of $1071.09 - Investor Newswire
07/07/16 05:22 AMCompany Stock Focus for FibroGen, Inc (NASDAQ:FGEN): Which Way Will Shares Head? - Press Telegraph
07/03/16 03:43 PMShare Performance Recap for: FibroGen, Inc. (NASDAQ:FGEN) - Press Telegraph
07/01/16 05:39 AMSales of $1071.09 expected for FibroGen, Inc (NASDAQ:FGEN) - Investor Newswire
06/29/16 03:57 PMFibroGen, Inc. Stock Momentum Hits Extreme Weakness - CML News
06/25/16 03:49 PMStock Tracing Lower on the Week FibroGen, Inc. (NASDAQ:FGEN) - Engelwood Daily
06/24/16 10:51 AMFibroGen, Inc (NASDAQ:FGEN) Earnings Glance and Target Price Review - Engelwood Daily
06/23/16 03:04 PMFibroGen, Inc (NASDAQ:FGEN) Yearly Sales Target At $1071.09 - Investor Newswire
06/22/16 08:42 AMFibroGen, Inc. (NASDAQ:FGEN) Went Down -1.69%: Infinity Pharmaceuticals, Inc. (NASDAQ:INFI), Tesla Motors Inc ... - KC Register
06/15/16 08:43 AMFibroGen, Inc (NASDAQ:FGEN) Trading Down – Insider Trading Activity
06/10/16 04:30 PMFIBROGEN INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote of Securi -
06/10/16 06:22 AMFibroGen, Inc. (NASDAQ:FGEN) Near to Lift Curtain on June 2016 Earnings - iStreetWire
06/09/16 06:19 AMFibroGen Announces Initiation by Astellas of Phase 3 Clinical Study in Japan of Roxadustat/ASP1517 for the Treatment of Anemia of Chronic Kidney Disease Triggering $10.0 Million Milestone Payment - [at noodls] - SAN FRANCISCO, June 09, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (Nasdaq:FGEN) ('FibroGen'), announced today that it will receive a $10.0 million milestone payment from Astellas Pharma Inc. (Astellas). ...
06/09/16 06:07 AMFIBROGEN INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits -
06/06/16 03:53 PMFIBROGEN INC. (NASDAQ:FGEN) Financial Condition Compared to S&P 500 - CML News
06/06/16 06:08 AMFibroGen to Present at the Goldman Sachs 37th Annual Global Healthcare Conference - [at noodls] - SAN FRANCISCO, June 06, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), announced that Chief Executive Officer, Thomas B. Neff, will be presenting at the Goldman Sachs 37th Annual Global Healthcare ...
06/03/16 10:11 PMFibroGen Inc (FGEN) CEO Sells $512730.00 in Stock - Let Me Know About This
06/03/16 07:07 AMFibroGen, Inc. breached its 50 day moving average in a Bullish Manner : FGEN-US : June 3, 2016 -
06/02/16 10:05 PMNews Sentiment For FibroGen, Inc (NASDAQ:FGEN) - Investor Newswire - News Sentiment For FibroGen, Inc (NASDAQ:FGEN)Investor NewswireFor measuring this sentiment, the news is tracked from different channels. But it has to be noted that only the most relevant and buzzing articles are considered to get a rational sentiment score. FibroGen, Inc (NASDAQ:FGEN) has been given a sentiment ...and more »
05/29/16 01:00 PMChairman’s Message during the FPH meeting on May 23, 2016 - [at noodls] - May 29, 2016 Six years ago we decided to express in a few words the vision of First Philippine Holdings Corp., which is to: 'Uplift lives through key industries and infrastructure that advance national ...
05/19/16 06:24 PMETF’s with exposure to FibroGen, Inc. : May 19, 2016 -
05/17/16 01:45 PMFibroGen, Inc. :FGEN-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/10/16 11:09 AMEdited Transcript of FGEN earnings conference call or presentation 9-May-16 8:30pm GMT -
05/09/16 03:46 PMFIBROGEN INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits -
05/09/16 03:18 PMFibroGen Reports Financial Results for the First Quarter of 2016 - [at noodls] - Continued Progress in Roxadustat Phase 3 Studies; Promising Interim Pancreatic Cancer Data -Webcast Conference Call Scheduled for 4:30pm EST Today- SAN FRANCISCO, May 09, 2016 (GLOBE NEWSWIRE) -- FibroGen, ...
05/09/16 06:07 AMQ1 2016 FibroGen Inc Earnings Release - After Market Close -
05/02/16 03:30 PMFibroGen to Report First Quarter 2016 Financial Results on May 9, 2016 - [at noodls] - SAN FRANCISCO, May 02, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a research-based biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics ...

Social

About FibroGen

FibroGen logoFibroGen, Inc. is a research-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200. FG-4592 is an oral small molecule inhibitor of hypoxia-inducible factor-prolyl hydroxylases (HIF-PHs), which acts by stimulating the body's natural pathway of erythropoiesis or red blood cell production. FG-4592 is in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD). FG-3019 is a monoclonal antibody, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), pancreatic cancer, Duchenne muscular dystrophy (DMD) and liver fibrosis. FG-6874 is in Phase I clinical trials, and FG-5200 is a corneal implant medical device, which is in preclinical studies.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: FGEN
  • CUSIP:
Key Metrics:
  • Previous Close: $19.13
  • 50 Day Moving Average: $16.95
  • 200 Day Moving Average: $18.52
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $1.19B
  • Beta: 1.15
  • Current Year EPS Consensus Estimate: $-1.02 EPS
  • Next Year EPS Consensus Estimate: $-1.47 EPS
Additional Links:
FibroGen (NASDAQ:FGEN) Chart for Friday, July, 29, 2016